Nuvation Bio Inc. (NUVB): Price and Financial Metrics
GET POWR RATINGS... FREE!
NUVB Stock Price Chart Interactive Chart >
NUVB Price/Volume Stats
| Current price | $3.53 | 52-week high | $14.50 |
| Prev. close | $3.47 | 52-week low | $3.40 |
| Day low | $3.40 | Volume | 579,100 |
| Day high | $3.60 | Avg. volume | 864,209 |
| 50-day MA | $4.88 | Dividend yield | N/A |
| 200-day MA | $7.22 | Market Cap | 773.28M |
Nuvation Bio Inc. (NUVB) Company Bio
Nuvation Bio Inc. operates as a bio-pharmaceutical company. The Company focuses on developing oncology medicines that will improve patient lives by addressing drug resistance. Nuvation Bio serves patients worldwide.
Latest NUVB News From Around the Web
Below are the latest news stories about Nuvation Bio Inc that investors may wish to consider to help them evaluate NUVB as an investment opportunity.
Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateNEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update. “In 2021, the Nuvation Bio team made significant progress for our lead cyclin-dependent kinase 2/4/6 inhibitor program in the clinic. NUV-422 received FDA Fast Track De |
Nuvation Bio GAAP EPS of -$0.12 in-lineNuvation Bio press release (NUVB): Q4 GAAP EPS of -$0.12 in-line.Strong balance sheet with cash, cash equivalents and marketable securities of $765.4 million as of December 31, 2021. |
Banks - Nuvation Bio Inc. Shares Purchased by Citigroup IncCitigroup Inc. boosted its position in Nuvation Bio Inc. by 104.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned… |
Fund - Nuvation Bio Inc. Shares Purchased by Citigroup IncCitigroup Inc. boosted its position in Nuvation Bio Inc. by 104.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned… |
Nuvation (NUVB) Gets FDA Clearance for Oncology CandidateNuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types following IND clearance by the FDA. |
NUVB Price Returns
| 1-mo | -26.92% |
| 3-mo | -33.77% |
| 6-mo | -60.38% |
| 1-year | -75.18% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -58.47% |
| 2021 | -27.35% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...